Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Navigators, Reminders May Improve Follow-Up After Positive Fecal Blood Test

October 12, 2017
By Leah Lawrence
Article

Follow-up intervention by patient navigators or provider reminders may help to improve the number of patients who undergo colonoscopy after positive fecal blood test results.

Follow-up intervention by patient navigators or provider reminders may help to improve the number of patients who undergo colonoscopy after positive fecal blood test results, according to the results of a review published in Annals of Internal Medicine.

“Timely diagnostic colonoscopy after a positive fecal test result is a critical step on the colorectal cancer screening continuum,” wrote Kevin Selby, MD, of Kaiser Permanente Division of Research in Oakland, California, and colleagues. “Although research has primarily focused on screening completion, fecal testing will not be effective if positive results are not followed.”

With this review, Selby and colleagues evaluated interventions that could improve follow-up rates after positive fecal blood tests. They reviewed 23 studies that reported data from an intervention for colonoscopy follow-up of asymptomatic adults with positive fecal test results. The studies included seven randomized and 16 nonrandomized studies.

Much of the research was of low-quality, the researchers noted, particularly with regard to system-level interventions, such as automated referral, patient registries, and quality improvement efforts. However, the study did reveal moderate evidence that supported the implementation of patient- and provider-level interventions.

The evidence suggested that the use of patient navigators, or individuals who work with patients to counsel and guide them through the barriers associated with cancer care, can increase rates of follow-up colonoscopy. The review included five studies of patient navigation interventions. One study compared usual care with or without the addition of a registered nurse patients navigator. Use of a navigator to help with logistic barriers and to conduct motivational interview resulted in a non-significant but clinically relevant increase in the number of patients completing colonoscopies.

“Patient navigators can provide one-on-one education and individualized reduction of structural barriers,” the researchers wrote. “Cost may be a limiting factor, however: An economic evaluation concluded that patient navigation for the follow-up of abnormal results on cancer screening tests costs an additional $275 per patient (CI, $260 to $290).”

Provider-level interventions that utilize electronic reminders to alert physicians of patients who have not taken adequate action after a positive test result were shown to improve colonoscopy completion from 9 to 25 percentage points.

Based on these results, the researchers concluded that “more research is needed given the critical role of the diagnostic resolution of positive test results in fecal blood-based screening.”

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Related Content

Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.

Real-World Data Show Activity With Ivosidenib in IDH1+ Cholangiocarcinoma

Kyle Doherty
July 11th 2025
Article

Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Tislelizumab Combo Improves Outcomes in Locally Advanced ESCC Subgroups

Kristi Rosa
July 10th 2025
Article

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.

Encorafenib Combo Yields Efficacy Across BRAF V600E+ CRC Subgroups

Kristi Rosa
July 9th 2025
Article

Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.


The liposomal formulation of gemcitabine may enhance anti-tumor activity by increasing plasma half-life and improving targeted delivery to tumors.

FDA Grants Orphan Drug Designation to FF-10832 in Biliary Tract Cancer

Tim Cortese
July 8th 2025
Article

The liposomal formulation of gemcitabine may enhance anti-tumor activity by increasing plasma half-life and improving targeted delivery to tumors.

Related Content

Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.

Real-World Data Show Activity With Ivosidenib in IDH1+ Cholangiocarcinoma

Kyle Doherty
July 11th 2025
Article

Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Tislelizumab Combo Improves Outcomes in Locally Advanced ESCC Subgroups

Kristi Rosa
July 10th 2025
Article

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.

Encorafenib Combo Yields Efficacy Across BRAF V600E+ CRC Subgroups

Kristi Rosa
July 9th 2025
Article

Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.


The liposomal formulation of gemcitabine may enhance anti-tumor activity by increasing plasma half-life and improving targeted delivery to tumors.

FDA Grants Orphan Drug Designation to FF-10832 in Biliary Tract Cancer

Tim Cortese
July 8th 2025
Article

The liposomal formulation of gemcitabine may enhance anti-tumor activity by increasing plasma half-life and improving targeted delivery to tumors.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.